CHICAGO--(BUSINESS WIRE)-- #cre--The life sciences real estate market is undergoing significant changes as supply outpaces demand, influencing rental growth, vacancy rates, and investment trends. The overall vacancy rate across major life sciences markets reached 20.5% in Q4 2024, up 250 basis points from Q2 2024. The total U.S. market saw negative net absorption for the second consecutive year, though key markets like Boston, Chicago, and Los Angeles-Orange County posted positive absorption in 2024.
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Greystone and Cushman & Wakefield jointly announced they provided acquisition financing for, and arranged the sale of, respectively, Country Place Apartments, a 312-unit multifamily property in Burtonsville, Maryland.
The headline numbers for Cushman & Wakefield (CWK) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cushman & Wakefield (CWK) came out with quarterly earnings of $0.48 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.45 per share a year ago.
DALLAS--(BUSINESS WIRE)-- #cre--Cushman & Wakefield announced that Todd Savage has joined the real estate services firm as Executive Managing Director of Office Investment Sales.
Cushman & Wakefield (CWK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CHICAGO--(BUSINESS WIRE)-- #cre--Cushman & Wakefield (NYSE: CWK) will release its fourth quarter and full year 2024 financial results at approximately 7:00 a.m. ET on Thursday, February 20, 2025. Management will host a conference call following the release at 9:00 a.m. ET on Thursday, February 20, 2025, to discuss the financial results. The conference call can be accessed as follows: Dial in to 1-844-825-9789 (domestic) or 1-412-317-5180 (international), or click here (link will be activated 15 mi.
I maintain a Hold rating on Cushman & Wakefield stock after analyzing its third quarter financial results and its progress relating to deleveraging. The company's Q3 2024 EPS was boosted by non-operating items such as lower interest expenses. Cushman & Wakefield's normalized EBITDA declined by 5.0% YoY in Q3, which is roughly the same as the company's -4.9% YoY EBITDA decline for Q2.
Cushman & Wakefield (CWK) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.21 per share a year ago.
Cushman & Wakefield (CWK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.